Jaguar Health, Inc. (NASDAQ:JAGX)

COMMUNIQUÉ DE PRESSE

publié le 10/12/2025 à 15:00, il y a 1 mois 20 jours

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026

Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea FDA Renewal
BRÈVE

publiée le 08/12/2025 à 22:20, il y a 1 mois 21 jours

Jaguar Health Announces Approval of Proposals at Stockholder Meeting

Crofelemer Microvillus Inclusion Disease FDA Approval Jaguar Health Stockholder Meeting
BRÈVE

publiée le 08/12/2025 à 22:20, il y a 1 mois 21 jours

Jaguar Health annonce l'approbation de propositions lors de l'assemblée générale des actionnaires

Crofelemer Jaguar Health Approbation De La FDA Assemblée Générale Des Actionnaires Maladie À Inclusions Microvillositaires
COMMUNIQUÉ DE PRESSE

publié le 08/12/2025 à 22:15, il y a 1 mois 21 jours

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Jaguar CEO Lisa Conte to present updates on near-term catalysts at Emerging Growth Conference; Initial results show crofelemer may extend infants' lives with MVID; Jaguar completes FDA meeting on crofelemer trial for MVID treatment

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference MVID
BRÈVE

publiée le 02/12/2025 à 15:05, il y a 1 mois 28 jours

Jaguar Health Seeks EMA Approval for Canalevia to Treat Dog Diarrhea

Jaguar Health European Medicines Agency Dog Diarrhea Canalevia Approval Non-antibiotic Treatment
BRÈVE

publiée le 02/12/2025 à 15:05, il y a 1 mois 28 jours

Jaguar Health sollicite l'approbation de l'EMA pour Canalevia dans le traitement de la diarrhée canine

Jaguar Health Agence Européenne Des Médicaments Diarrhée Du Chien Approbation De Canalevia Traitement Non Antibiotique
COMMUNIQUÉ DE PRESSE

publié le 02/12/2025 à 15:00, il y a 1 mois 28 jours

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap

Jaguar Health Dogs EMA Canalevia General Diarrhea
BRÈVE

publiée le 24/11/2025 à 15:05, il y a 2 mois 6 jours

Jaguar Health renforce sa propriété intellectuelle grâce à un nouveau brevet pour le crofélémère dans le traitement des troubles intestinaux.

Crofelemer Jaguar Health Essais Cliniques Brevet Troubles Intestinaux
BRÈVE

publiée le 24/11/2025 à 15:05, il y a 2 mois 6 jours

Jaguar Health Strengthens IP with New Patent for Crofelemer in Intestinal Disorders

Crofelemer Patent Clinical Trials Jaguar Health Intestinal Disorders
COMMUNIQUÉ DE PRESSE

publié le 24/11/2025 à 15:00, il y a 2 mois 6 jours

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Jaguar Health, Inc. secures new patent expanding international IP for crofelemer in pediatric intestinal failure disorders, highlighting reductions in parenteral support. Supporting business development plans

Crofelemer Business Development Jaguar Health Inc. Pediatric Intestinal Failure New Patent

Publié le 30/01/2026 à 18:40, il y a 19 minutes

ICADE - Bilan semestriel du contrat de liquidite
Publié le 30/01/2026 à 18:01, il y a 58 minutes

Emova Group - Résultats annuels 2024/25
Publié le 30/01/2026 à 17:45, il y a 1 heure 14 minutes

Schneider Electric launches a capital increase reserved for employees
Publié le 30/01/2026 à 17:45, il y a 1 heure 14 minutes

Schneider Electric lance une augmentation de capital réservée aux salariés
Publié le 30/01/2026 à 08:30, il y a 10 heures 29 minutes

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

Voir tout LES ECHOS COMFI WIRE

Publié le 30/01/2026 à 14:00, il y a 4 heures 59 minutes

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Publié le 30/01/2026 à 08:35, il y a 10 heures 24 minutes

Alaska Energy Metals Announces Closing Of Life Offering of Units
Publié le 30/01/2026 à 08:00, il y a 10 heures 59 minutes

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Publié le 30/01/2026 à 02:15, il y a 16 heures 44 minutes

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Publié le 30/01/2026 à 00:00, il y a 18 heures 59 minutes

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

Voir tout ACCESSWIRE

Publié le 30/01/2026 à 18:31, il y a 27 minutes

Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 30/01/2026 à 18:30, il y a 28 minutes

HOL-Holdings in Company
Publié le 30/01/2026 à 18:23, il y a 35 minutes

TVR-Total Voting Rights
Publié le 30/01/2026 à 18:17, il y a 41 minutes

POS-Transaction in Own Shares
Publié le 30/01/2026 à 18:17, il y a 41 minutes

Holding(s) in Company

Voir tout EQS

News